NIKKEI 225
26,871.27 +379.30 (+1.43%) HANG SENG
22,229.52 +510.46 (+2.35%) CRUDE OIL
110.16 +2.54 (+2.36%) GOLD FUTURES
1,825.30 -5.00 (-0.27%) DOW
31,518.65 +17.97 (+0.06%) BTC-GBP
16,898.10 -540.98 (-3.10%)
Novavax, Inc. (NVAX)
| Previous close | 51.67 |
| Open | 51.91 |
| Bid | 52.86 x 3000 |
| Ask | 53.01 x 1000 |
| Day's range | 50.20 - 53.70 |
| 52-week range | 34.88 - 277.80 |
| Volume | |
| Avg. volume | 6,009,316 |
| Market cap | 4.176B |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
3 Reasons to Buy Novavax and 1 to Sell
Novavax (NASDAQ: NVAX) is a pandemic stock. Now it's down to $50, and the company's market cap is under $4 billion. Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.
- Motley Fool
5 Unique Stocks That Can Generate Transformational Wealth
As much as you might hate to hear this, stock market corrections and bear markets are a perfectly normal part of the investing cycle. Including the current bear market decline that the benchmark S&P 500 and tech-focused Nasdaq Composite are navigating their way through, the broader market has dropped by a double-digit percentage, on average, every 1.85 years since the beginning of 1950. Despite corrections being commonplace, the amount of time Wall Street spends in a bull market handily outpaces periods of pessimism.
- Motley Fool
Why Sanofi May Be a Frontrunner in Endemic COVID-19
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.
